Periodontal Disease – Drug Pipeline Landscape, 2022
Periodontal disease is also called as gum disease. It is a set of infections and inflammatory condition affecting the tissue of the gum and the bones that surround and support the teeth.
They are two types of periodontal diseases which includes – gingivitis and periodontitis. Gingivitis is an early stage condition where gums become swollen, red and bleed. Periodontitis is a serious form where gum can pull away from the tooth, weaken jaw bone and the teeth may loosen or fall out.
The main cause of periodontal disease is due to the bacteria in the mouth which infects the tissue around the teeth. Factors that increase the risk include poor oral hygiene, diabetes, infectious diseases like HIV/AIDS, smoking, and certain medications.
Symptoms includes swollen or puffy gums, bleeding gums, bad breadth, pus formation, loose teeth, painful chewing.
Treatment involves removing the plaque and bacterial deposits on teeth and gums. If the condition isn’t advanced, treatment involves scaling, root planning and antibiotics, topical or oral. If the condition is advanced, treatment involves dental surgery.
Global Insight Service’s, Periodontal Disease – Drug Pipeline Landscape, 2022 report provides an overview of the Periodontal Disease pipeline drugs. This report covers detailed insights on Periodontal Disease drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Periodontal Disease pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
- Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
- Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
- Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
- Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Table of Contents
List of Tables
List of Figures
1.1 Periodontal Disease – Pipeline Drugs, 2022-Coverage
2. Disease Overview – Periodontal Disease
2.2 Signs and Symptoms
2.4 Disease Management
3. Periodontal Disease – Pipeline Drugs Development – Overview
3.1 Comparative Analysis by Stage of Development
3.2 Number of Products under Development by Companies, 2022
3.3 Products under Development by Companies, 2022
4. Assessment of Therapeutics
4.1 Assessment by Target
4.2 Assessment by Mechanism of Action
4.3 Assessment by Molecule Type
4.3 Assessment by Route of Administration
5. Drug Profiles
5.1 Clinical Stage Drugs – Phase II
5.2 Clinical Stage Drugs – Phase I
5.2.1 Cellistem ER
5.3 Early Stage Drugs – Preclinical
5.3.2 human dental pulp mesenchymal stem cells
5.3.6 Vaccines for periodontal disease
5.4 Early Stage Drugs – Discovery
6. Key Regulatory Designations
7. Key Deals
8. Key Upcoming Milestones
9. Key Companies Involved
9.1 Amyndas Pharmaceuticals S.A.
9.2 Beijing SH Biotechnology Co., Ltd.
9.3 Cellatoz Therapeutics Inc
9.4 Cells for Cells SA
9.5 D&D Pharmatech
9.6 Denteric Pty Ltd
9.7 GEXVal Inc
9.8 KIMS Pharmaceutical Co., Ltd
9.9 MetiMedi Pharmaceuticals Co Ltd
9.10 Noveome Biotherapeutics
9.11 PerioTrap Pharmaceuticals GmbH
10. Dormant Drugs
10.1 Inactive Drugs
10.2 Discontinued Drugs
List of Tables
Table 1. 2 Number of Products under Development by Companies
Table 1. 3 Products under Development by Companies
Table 1. 4 Products by Targets
Table 1. 5 Products by Mechanism of Action
Table 1. 6 Products by Molecule Type
Table 1. 7 Products by Route of Administration
Table 2.1 Clinical Trial Details – AMY-101/Amyndas Pharmaceuticals S.A.
Table 2.2 Clinical Trial Details – ST266/Noveome Biotherapeutics
Table 3. 1 Regulatory Designations
Table 4. 1 Inactive Drugs
Table 4. 2 Discontinued Drugs
List of Figures
Figure 1. 1 Number of Products under Development for Periodontal Disease, 2022
Figure 1. 2 Products by Top 5 Targets and Stage of Development for Periodontal Disease, 2022
Figure 1. 3 Products by Top 5 Mechanism of Action and Stage of Development for Periodontal Disease, 2022
Figure 1. 4 Products by Top 5 Molecule Type and Stage of Development for Periodontal Disease, 2022
Figure 1. 5 Products by Top 5 Route of Administration and Stage of Development for Periodontal Disease, 2022
• Amyndas Pharmaceuticals S.A.
• Beijing SH Biotechnology Co., Ltd.
• Cellatoz Therapeutics Inc
• Cells for Cells SA
• D&D Pharmatech
• Denteric Pty Ltd
• GEXVal Inc
• KIMS Pharmaceutical Co., Ltd
• MetiMedi Pharmaceuticals Co Ltd
• Noveome Biotherapeutics
• PerioTrap Pharmaceuticals GmbH
- Assessment by Stage of Development
- Assessment by Companies
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Molecule Type
- Assessment by Route of Administration